
    
      Initially, patients will be treated with oral CC-223 for one month. During this time, various
      tests (involving blood and urine collections, ECGs, etc) will be performed. Those whose
      tumors stabilize or regress may continue receiving treatment for as long as they benefit from
      CC-223. Different dose levels of CC-223 will be tested in a dose-rising study design.
    
  